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which androgen dependence is lost (1, 7) and cell proliferation is
mainly stimulated by locally synthesized growth factors. A variety of
growth stimulatory factors have been shown to be produced by human
androgen-independent prostatic tumors (8â€”14).In these conditions,
conclusive indications for successful therapy are still lacking. A better
understanding of the local mechanisms involved in the control of the
growth of androgen-independent tumors will certainly be of help in
improving therapeutic options.
The present experiments have been performed to verify whether
LHRH agonists might also affect the proliferation of prostatic carci
noma when the tumor has lost its androgen dependence. Advantage
has been taken of the existence of the DU 145 cell line, which was
derived from a brain metastasis of a human prostatic adenocarcinoma;
this cell line retains the androgen independence of the original tumor
(15â€”17),and does not possess androgen receptors (18). The expres
sion of a functional LHRH-like system (LHRH mRNA and LHRH
receptors) as well as the possible role played by this system in the
local mechanisms regulating DU 145 cell proliferation have also been
investigated.
MATERIALS AND METhODS
Materials
LHRH agonists Zoladex (D-Ser(tBu)6Aza-Gly-LHRH)and Buserelin (D
Ser(tBu)6Des-Gly'Â°-LHRH-N-ethylaznide) were kindly donated by Zeneca
(Milano, Italy) and Hoechst A. G. (Frankfurt, Germany), respectively. LHRH
antagonist (NaI-Arg-LHRH) was kindly provided by Dr. W. V. Vale (The Salk
Institute, La Jolla, CA).
Animals
Adult male Sprague-Dawley rats were obtained from Charles River (Calco,
Como, Italy). Animals were maintained on a 14-h light/b-h dark schedule,
with standard pellet food and water available ad libitum. All rats were killed
by decapitation; hypothalami and pituitaries were quickly collected and frozen
at â€”70Â°Cuntil membrane preparation for LHRH receptor assays, and RNA
extraction for the RT-PCR studies.
Cell Culture
The cell line DU 145 was obtained from American Type Culture Collection
(Rockville, MD). Cells (passages 60â€”70)were routinely grown in RPMI-1640
medium (Seromed, Biochrom KG, Berlin, Germany) supplemented with 5%
FcS (Gibco, Paisley, Scotland), glutamine (1 mM), and antibiotics (100
units/mI penicillin G sodium, 100 @Wmlstreptomycin sulfate) in a humidified
atmosphere of 5% C02:95% air. In these conditions the duplication period of
the cells is 36 h.
LLIRH Agonists and DU 145 Cell Proliferation
DU 145 cells were plated at a density of 500â€”800cells/cm2 in 100-mm
dishes in RPMI-1640 medium supplemented with 5% FCS. Cells were allowed
to attach and start growing for 3 days; the seeding media were then changed to
experimental media.
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ABSTRACT
The therapeutic options for the treatment of androgea-independent
prostatic cancers are rather limited; this Is mainly because our under
standing of the local mechanisms involved In the control of androgen
independent proliferation of the tumor is stlH very poor. The present
experlmeats have been performed to verify whether luteinizing hormone
releasing hormone (LHRH) agonists may possess a direct effect on the
growth of the human androgen-independeat prostate cancer cells DU 145
and whether a LHRH growth regulatory system may be present in these
cells. The data have shown that two potent LHRII agonists (Zoladex and
Buserelin) exert a significant and dose-dependent andproliferative action
on DU 145 cells, after 4 days of treatment. The inhibitory action of
Zoladex and Buserelin is completely counteracted by the simultaneous
treatment of the cells with a potent LHRH antagonist, suggesting that the
action of the LHRH agoaists may be mediated by specific receptors. This
hypothesis has been confirmed by the demonstration that low-affinity
binding sites for lasI@Buserelin are present on DU 145 cell membranes,
particularly when cells are cultured in serum-free conditions. By using the
reverse transcriptlon-polymerase chala reaction technique, in the pros
eace of a pair of specificollgonucleotldeprimerscomplementaryto the
human LHRH complementary DNA, it has been demonstrated that a
mRNA for LHRH Is expressed In DU 145 cells. Taken together, these data
seem to indicate that an autocrine/paracrine LHRH (or UIRH-llke) loop
is present in androgea-independent prostate cancer cells, and may par
ticipate in the regulation of tumor cell growth. To verify this hypothesis,
DU145cellshavebeenculturedinserum-freeconditions,andtreatedwith
a LHRHantagonistfor 4 days. The treatmentresultedin a significant
increase of cell proliferation, suggesting an inhibitory role for the LHRH
system in the local regulation of cell growth.
In conclusion, these data demonstrate that: (a) LHRH agonists exert a
specific antiproilferative action on the human androgen-independent DU
145 calls; (b) an autocrine/paracrine LHRH (or LIIRH.like) loop, which
seems to be Inhibitory on cell proliferation, is expressed in DU 145 cells.
INTRODUCTION
Prostatic cancer is usually androgen dependent in its early stages,
and consequently testosterone withdrawal represents initially the ther
apy ofchoice (1â€”5).LHRH3 agonists are widely and successfully used
for the treatment of this pathology on the basis of their ability to
suppress the activity of the pituitary-testicular axis and, therefore, to
reduce testosterone secretion (2, 6).
In later stages, prostatic carcinoma may progress to a condition in
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UIRH AND DU 145 CELLS
Experiment 1. Cells were treated daily, for 4 days, with Zoladex or
Buserelin (10_h1_10_6 M,500 @l),while the medium was changed every 2
days. At the end of the treatment, cells were harvested and counted by
hemocytometer.
Experiment 2. To verify the specificity of the effect of LHRH agonists on
DU 145 cell proliferation, cells were treated daily with Zoladex or Buserelin
(10_8 M, 500 pi) either in the absence or presence of ANT (10_8 M, 500 @il).
After 4 days of treatment, cells were harvested and counted.
LHRH Receptors
DU 145 cells were grown in serum-freeconditions (RPMI-1640medium
supplemented with 6.25 @g/mlof insulin and transferrin, 6.25 ng/ml of
selenious acid, and 1.25 mg/ml of bovine serum albumin) (10). The LHRH
radioreceptor assay was performed as previously described (19, 20), by using
@I-Buserelin (specific activity, 800â€”1000 @Ci/@g)as the specific ligand.
Briefly, displacement curves were performed by incubating 100-@tlcell mem
brane aliquot with â€˜@I-Buserelin (â€”200,000 cpm) either in the absence or
presence of increasing concentrations of Buserelin (10@â€”10@ M). Nonspe
cific binding was determined in the presence of iO@ Munlabeled Buserelin.
Displacement curves allowed the determination of binding characteristics for
LHRH receptors (Kd dissociation constant; Bm,,, maximum concentration
of binding sites) on DU 145 cells. LHRH receptors have also been analyzed on
male rat pituitariesused as controls.The proteincontent of each membrane
preparation was evaluated according to the method of Bradford (21).
RNA Extraction and RT-PCR
Total RNA was extracted from DU 145 cells as well as from rat hypothal
ami and pituitaries (jositive and negative controls, respectively) according to
a modification of the guanidium thiocyanate/cesium chloride method (22).
RT.PCRwas performedas previouslydescribed(23). Briefly, RNAs (1 @g)
extracted from DU 145 cells, rat hypothalami and pituitaries were reverse
transcribed into cDNAs with an oligodeoxythymidylate [oligo(dT)16Jas a
primer, using the Gene AMP kit (Perkin Elmer Cetus, Norwalk, CT). The
cDNAs obtained were then amplified in the presence of Taq polymerase and
a pair of specific printers (23), according to the instructions of the manufac
turer. The primers were synthesized according to the reported human and rat
LHRH cDNA sequences (24). The sequence of the primers has been chosen to
span two introns of the LHRH genomic structure, in order to avoid contami
nation by genomic DNA. Amplification was carried out for 35 cycles (1-mm
denaturation at 94Â°C, 1-min primer annealing at 50Â°C, and 3-mm primer
extension at 72Â°C). According to the sequence of the primers, a 228-base pair
fragment was expected after RT-PCR amplification of the LHRH message. As
negative controls, samples containing no mRNA were subjected to the same
RT-PCRprocedure;these samplesdid not give rise to any detectableproduct.
Aliquots of 10 @lof the RT-PCR psoducts were electrophoresed on a 1.5%
agarose gel, stained with ethidium bromide and Southern blotted as described
(25). Blots were then hybridized with a 32P-labeled oligonucleotide (17 mer)
probe complementary to a sequence (nucleotides 159/175) which is common to
the human and rat LHRH cDNA (23, 24).
LHRH Antagonist and DU 145Cell Proliferation in Serum-free
Conditions
DU 145 cells were platedat a density of 2.5 X 10@cells/cm2 in 100-mm
dishes in serum-free conditions, as described for LHRH receptor studies. Cells
were treated daily with ANT (10_12_10_6 M, 500 pi); the medium was
changed every 2 days. After 4 days of treatment the cells were harvested and
counted.
Statistical Analysis
The data from experiments involving cell proliferation were analyzed ac
cording to Dunnett's test (26) after one-way analysis of variance. The data
from displacementcurves for LHRHreceptorswere analyzedby the Ugand
program (27) which allows the determination of Kd and Bm@values for the
receptors under study.
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Fig. 1. Effects of two LHRH agonists Zoladex [Z(a)J and Buserelin [B(b)J on the
proliferation of DU 145 cells, after 4 days of treatment. Results are expressed as the mean
cell number per plate Â±SE. C, controls without drugs. @,@D< 0.05 versus C.
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RESULTS
LHRH Agonists and DU 145 Cell Proliferation
Experiment 1. The effects of a 4-day treatment with the two
LHRH agonists Zoladex and Buserelin (10_h1_10_6 M) on DU 145
cell proliferation are reported in Fig. 1. Both analogues inhibited cell
growth in a dose-dependent fashion. The antiproliferative action of
both LHRH agonists was signfficant versus controls at doses ranging
from i09 to 10_6 M;Buserelin was significantly effective also at the
dose of 10â€”â€˜Â°M (Fig. lb).
Experiment 2. To verify the specfficity of the antiproliferative
action of LHRH agonists on DU 145 cells, it has been investigated
whether the inhibitory effect of Zoladex and Buserelin could be
counteracted by the simultaneous treatment of the cells with an LHRH
antagonist. In preliminary experiments, the effects of a treatment with
ANT on DU 145 cell proliferation have been studied. Cells were
treated for 4 days with ANT at different doses (10 12_10_6 M). None
of the doses used proved able to modify cell proliferation (data not
shown). The intermediate dose of 108 M was then selected for the
following experiments. Fig. 2a confirms that ANT (10_8 M) is inef
fective and that Zoladex (10_8 M) significantly inhibits cell prolifer
ation. Fig. 2a also shows that, when the two compounds are given
together, ANT completely counteracts the inhibitory effect of Zola
dcx. Similar results have been obtained by treating the cells with
Buserelin, at the same doses, either in the absence or presence of ANT
(Fig. 2b).
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a crineroleoncellproliferation,theeffectsofANTontheproliferation
10 of DU 145 cells cultured in serum-free conditions were studied. Cells
were treated daily with different doses of ANT (10 12_1O_6 M)for 4
8 days. Fig. 5 shows that the treatmentwith ANT at two dose levels
m (10_8 and 1O_6 M) is followed by a significant increase of cell
is 6 proliferation;lower concentrationsof ANT (10 12and 10 â€˜Â°M)
@ proved inactive.
@ DISCUSSION
The present results show that the growth of the human androgen
â€” .@@ - independent prostatic cancer cell line DU 145 is significantly inhib
0@ ANT ited by treatment with two potent LHRH agonists (Zoladex and
Buserelin). The antiproliferative action of the two drugs is dose
b dependenta dspecific,sinceit iscompletelycounteractedbythe
simultaneous treatment of the cells with a potent LHRH antagonist. In
contrast with these observations, Qayum et a!. (30) have reported that
a treatment with various doses (from 10 â€˜Â°to i07 M) of Buserelin
does not affect the proliferation of DU 145 cells. Differences in the
It experimental design adopted (i.e., cell culture conditions, length of the
I o@9
0.08k
C B ANT
Fig. 2. Effects ofANT(1O8 M)on the inhibition ofDU 145 cell proliferation induced@ o oi
by the LHRHagonistsZoladex[Z(a)] and Buserelin[B(b)l (i08 M).Resultsare@
expressed as the mean cell number per plate Â±SE. C, controls without drugs. @,@D< 0.05
versus C.
0.06
LHRH Receptors
Fig. 3 shows that binding sites for the LHRH analogue 1@I@
Buserelin are present on the membranes of DU 145 cells when these
are Cultured in serum-free conditions. Computer analysis ofthe data of
the displacement curves revealed the presence of a single class of
low-affinity (Kd 3-10 p@M),high-capacity (B,...@ = 425-668
pmol/mg protein) binding sites. Analysis of LHRH receptors on male
rat pituitaries, used as controls, showed the presence of a single class
of high-affinity (Kd 1 mi), low-capacity (Bmas 150170 fmol/mg
protein) binding sites, confirming previous data of this and other
laboratories (28, 29).
Expression of LHRH mRNA
After the RT-PCR procedure, the cDNAs obtained from DU 145
cells and from rat hypothalami and pituitaries were separated on a
1.5% agarose gel, Southern blotted, and hybridized with a 32P-labeled
LHRH oligonucleotide (17 mer) probe. A 228-base pair cDNA frag
ment was obtained from DU 145 cells as well as from rat hypothal
ami; no amplification product of this size could be obtained from rat
pituitaries. Fig. 4 shows that the cDNA fragments obtained from two
samples of DU 145 cells (Lanes 2 and 3), and from one sample of rat
hypothalamus (Lane 4) specifically hybridize with the 32P-labeled
LHRH probe; no hybridization band is present in the pituitary lane
(Lane 1).
LHRH Antagonist and DU 145 Cell Proliferation in Serum-free
Conditions
z +ANT
L}1R.HAND DU 145 CELLS
KdI0@tM
.
4 4 -d@ -2-10
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Fig. 3. Binding of â€˜@I-Buserelinto DU 145 cell membranes. The binding assay was
performed as described in â€œMaterialsand Methods.â€•Data were analyzed according to the
Ligand program. One representative curve, out of four binding experiments, is reported.
BIT, bound/total ratio. Kd, dissociation constant.
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Fig. 4. Autoradiography of the RT-PCR products Obtainedfrom rat pituitary (Lane 1),
DU 145cells(Lanes2 and3), andrat hypothalamus(Lane4) aftergel electrophoresis,
To verify whether the LHRH (or LHRH-like) system expressed in @uthemblotting,andhybridizationwitha specific32P-labeledoligonucleotideLHRH
DU 145 cells (LHRH receptors, LHRH mRNA) might play an auto- probe.
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LHRH AND DU 145 CELLS
The presence of LHRH receptors on DU 145 cells suggested that
LHRH, or a LHRH-like factor, might be produced by these cells. This
hypothesis has been confirmed by showing that a mRNA for LHRH
is expressed in DU 145 cells as well as in the rat hypothalamus used
as positive control. The observation that no mRNA for LHRH is
expressed in the rat pituitary gland is in line with previous observa
tions of the authors' (23) and other (36) laboratories. A mRNA for
LHRH is also expressed in the androgen-responsive prostate cancer
cell line LNCaP (23). In agreement with the present data, Qayum et al.
(30,37)haveshownthepresenceofLHRHimmunoreactivematerial
in the culture media of DU 145 cells. Taken together, all these data
suggest that an autocrine LHRH or LHRH-like loop (mRNA, LHRH
peptide, LHRH receptors), similar to the one expressed in LNCaP
cells, might be expressed also in androgen-independent prostatic
cancer cells.
To verify this hypothesis, and to clarify the possible role played by
this system in the local mechanisms regulating tumor growth, the
effects of potent ANT on the proliferation of DU 145 cells cultured in
serum-free conditions have been investigated. The treatment with
ANT resulted in a significant increase of cell proliferation. In the
authors' opinion, several major considerations can be drawn from
these data. First of all, DU 145 cells seem to express a functional
LHRH or LHRH-like system endowed with autocrine or paracrine
inhibitory properties on cell proliferation. Second, this LHRH-like
system seems to be expressed and/or active when the cells are grown
in the absence of FCS. Actually, as described in the present paper (see
â€œResultsâ€•),a similar treatment with ANT is completely devoid of any
effect on cells grown in standard conditions (RPMI-1640 medium
supplemented with 5% FCS). In this context, it is also interesting to
emphasize that LHRH receptors are detectable only on DU 145 cells
grown in serum-free conditions. These data seem to indicate that the
activity of the autocrine/paracrine LHRH-like inhibitory loop in DU
145 cells is regulated in a negative way by one or more factors present
in serum. Further experiments are now in progress in the authors'
laboratory to verify whether serum-derived growth factors might be
responsible for this negative regulation.
Recently, it has been reported that a similar LHRH-like inhibitory
loop is active in controlling the growth of the androgen-dependent
human prostatic cancer cell line LNCaP (20, 23). Moreover, receptors
for LHRH, and LHRH-like immunoreactive material, have been dem
onstrated to be present in specimens of human benign and malignant
prostatic tumor tissues (30, 37, 38), as well as in samples of experi
mental prostatic cancers (39, 40). Finally, it has been recently reported
that a mRNA for LHRH as well as a bioactive and immunoreactive
LHRH are also present in the normal prostate of the adult rat (41).
Taken together, these observations clearly point to LHRH as a local
growth regulatory factor, involved, possibly with an inhibitory activ
ity, in the mechanisms regulating the proliferation of both normal and
malignant prostatic tissues.
The fact that, under specific experimental conditions, LHRH an
tagonists may facilitate cell proliferation in prostatic cancer cell lines
(LNCaP, DU 145, etc.) suggests a word of caution in the clinical
utilization of these drugs. The authors do not want to overemphasize
their results, which might occur only in cells cultured in particular
conditions; however, the present and previous findings (23), suggest
that the relationships between LHRH antagonists and normal and
pathological cell proliferation in the prostate should be given partic
ular attention in the future.
In conclusion, the present data indicate that: (a) LHRH agonists
exert a direct antiproliferative action on the human androgen-inde
pendent prostate cancer cell line DU 145; (b) a LHRH or LHRH-like
growth inhibitory system is functionally expressed in these cells.
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Fig. 5. Effects of ANT (10 12_10_6 M) on the proliferation of DU 145 cells cultured
in serum-free conditions, after 4 days of treatment. Results are expressed as the mean cell
number per plate Â±SE. C, controls without drug. â€˜,P < 0.05 versus C.
ANT (log dose M)
treatment, etc.) might account for the discrepancies between these
results.
Recently, it has been shown in the authors' laboratory (20) that
Zoladex and Buserelin specifically inhibit the proliferation of the
androgen-dependent prostatic cancer cell line LNCaP. The sugges
tion was advanced that, when utilized for the treatment of prostatic
carcinoma, LHRH agonists might inhibit tumor growth not only by
suppressing the activity of the pituitary-testicular axis, and there
fore by inhibiting testosterone secretion, but also by acting directly
at the level of the tumor. The present data seem to suggest that
LHRH agonists might also exert this direct inhibitory action on the
growth of prostatic carcinoma when this has progressed to an
androgen-independent stage. It seems then possible to speculate
that LHRH agonists might be utilized also for the treatment of
androgen-independent prostatic tumors, because of their direct
effect on prostatic cell proliferation.
The fact that the inhibitory action of LHRH agonists on DU 145
cell proliferation is counteracted by the simultaneous treatment of the
cells with a LHRH antagonist led us to investigate whether receptors
for LHRH agonists might be expressed on these cells. By using
â€˜@I-Buserelinas the specific ligand, low-affinity LHRH binding sites
have been detected on DU 145 cells, particularly when cultured in
serum-free conditions. These observations are in line with those
reported by Qayum et al. (30) and are germane to previous observa
tions obtained in the authors' and other laboratories on the presence of
similar binding sites in the androgen-dependent prostate tumor cell
line LNCaP (20, 30). The presence of low-affinity LHRH binding
sites has also been reported for other human extrapituitary tissues,
both normal (gonads and placenta) (31â€”33)and tumoral (breast cancer
cells) (34, 35). The fact that, in the present studies, the concentration
of Buserelin required to displace â€˜@I-Buserelin(Kd = 10 p@M)is
higher than the doses of LHRH agonists able to elicit a biological
response on cell proliferation (10 Io_10_6 M), appears intriguing.
However, a similar dichotomy has been previously reported by
Limonta et aL (20), using LNCaP cells, and by Miller et aL (34), using
the human breast cancer cell line MCF-7. As pointed out also by
Miller et a!. (34), the different experimental conditions (e.g., culture
conditions, time, temperature, etc.) adopted for the binding assay and
for the evaluation of the biological effects might be responsible for
this discrepancy.
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